BDBM72422 3-[4-(1H-benzimidazol-2-yl)-1-piperidinyl]-1-(2-fluorophenyl)-2,5-pyrrolidinedione::3-[4-(1H-benzimidazol-2-yl)-1-piperidinyl]-1-(2-fluorophenyl)pyrrolidine-2,5-dione::3-[4-(1H-benzimidazol-2-yl)piperidin-1-yl]-1-(2-fluorophenyl)pyrrolidine-2,5-dione::3-[4-(1H-benzimidazol-2-yl)piperidino]-1-(2-fluorophenyl)pyrrolidine-2,5-quinone::MLS000624855::SMR000293597::cid_2950755

SMILES CC1CCNc2[nH]c(=O)ccc2N2CN(c3cc(C(F)(F)F)c(F)cc3C2=O)c2ccc(F)c(F)c21

InChI Key InChIKey=RZRHWLQMTDODOH-UHFFFAOYSA-N

Data  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 72422   

TargetSodium channel protein type 10 subunit alpha(Human)
Glaxosmithkline Intellectual Property Development

US Patent
LigandChemical structure of BindingDB Monomer ID 72422BDBM72422(2,8,9-Trifluoro-10-methyl-3-(trifluoromethyl)-10,1...)
Affinity DataIC50: 15.8nMAssay Description:Keywords: Heat Shock Factor-1 (HSF-1), Stress Response, MG132, NIH3T3, Luminescence Assay Overview: Modified NIH3T3, transformed to express firefly...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/16/2026
Entry Details
US Patent